Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.59 |
| ▸ | NQO2 | P16083 | 2/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23197679 | 0.84 | TDP1 (0.56) | GSK3BNQO2ALDH1A1MAPTKDM4E | |
| SCHEMBL18551784 | 0.83 | GSK3B (0.56) | GSK3BALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL4880543 | 0.81 | HPGD (0.69) | GSK3BALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL2319851 | 0.78 | TDP1 (0.48) | GSK3BNQO2ALDH1A1MAPTKDM4E | |
| SCHEMBL13680485 | 0.77 | PRMT1 (0.51) | GSK3BTSHR | |
| SCHEMBL13990243 | 0.77 | ALDH1A1 (0.70) | GSK3BALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL12578009 | 0.76 | TDP1 (0.67) | GSK3BALDH1A1MAPTKDM4EPKM | |
| SCHEMBL3500179 | 0.76 | KDM4E (0.64) | GSK3BNQO2EGFRALDH1A1MAPT | |
| SCHEMBL13680520 | 0.76 | LMNA (0.53) | GSK3BNQO2ALDH1A1MAPTKDM4E | |
| SCHEMBL12669250 | 0.76 | TDP1 (0.46) | GSK3BNQO2ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067669-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-02-29 | — | — | US | disclosed |
| US-20170136007-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | THE FEINSTEIN INST MEDICAL RES (US) | 2017-05-18 | — | — | US | disclosed |
| US-9428522-B2 | Piperazines, pharmaceutical compositions and methods of use thereof | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2016-08-30 | — | — | US | disclosed |
| US-20140343059-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2014-11-20 | — | — | US | disclosed |
| US-8822472-B2 | Piperazines, pharmaceutical compositions and methods of use thereof | CORNERSTONE THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067669-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | C1S, CHRM1, C1R | GSK3B 3951/4885NQO2 2415/4885EGFR 1602/4885 |
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | GSK3B 3430/4885NQO2 3941/4885EGFR 285/4885 |
| US-20140343059-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRNA2 | GSK3B 2322/4885NQO2 978/4885EGFR 4253/4885 |
| US-20170136007-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRM5 | GSK3B 4071/4885NQO2 1001/4885EGFR 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.